Post Profile

Genetic testing can help predict if chemo will work

Researchers say a new genetic test for breast cancer patients may indicate whether standard chemotherapy treatments will work. Their study, published in the Journal of the American Medical Association, suggests the key to treating breast cancer may lie in predicting whether a patient will respond to standard therapy based on his or her genetics or the genes [...]
read more


Related Posts

Research Makes It Possible to Predict How Cancers Will Respond to Chemo

Health : Newswise Medical News

Dana-Farber scientists have devised a test that can predict how effective chemotherapy will be by determining whether tumor cells are "primed" for death. The discovery suggests it may be possible to predict which patients will likel...

More research urged to compare and validate genomic tests for patients with early breast cancer

Health : Medical News Today

The European Society for Medical Oncology (ESMO) has welcomed preliminary clinical trial results that suggest genomic testing could allow many patients with early breast cancer to safely avoid chemotherapy. The new trial results[1],...

Two genes predict tumor's progression to invasive breast cancer

Health : LA Times: Health

A new genetic test may help determine whether a small tumor in the breast is likely to turn in to full-blown breast cancer, according to a study published Wednesday in the Journal of the National Cancer Institute.

Use Of Genetic Information May Help Predict Likelihood Of Survival Following Chemotherapy For Breast Cancer

Health : Medical News Today

Development of a predictive test that included genomic signatures that indicated chemoresistance, chemosensitivity and endocrine sensitivity for women with newly diagnosed breast cancer identified patients with a high probability of...

Myriad's HRD™ test significantly predicts response to cisplatin treatment in triple negative breast cancer patients in second research study

Health : Medical News Today

Myriad Genetics, Inc. presented clinical data at the 2013 San Antonio Breast Cancer Symposium that showed the Myriad's HRD (homologous recombination deficiency) test was significantly associated with cisplatin response in patients w...


Copyright © 2016 Regator, LLC